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d honoraria from BristoSummary Patients with advanced non-small-cell lung cancer (NSCLC) have a poor
prognosis and suffer many disease-related symptoms. Treatments should therefore
aim to palliate these symptoms as well as improve overall quality of life. Gefitinib
(‘Iressa’) is a novel epidermal growth factor receptor tyrosine kinase inhibitor that
targets cell signaling involved in tumor growth and differentiation. In Phase II trials
in recurrent NSCLC, gefitinib provided objective responses and symptom relief, and
was generally well tolerated. Now approved for the treatment of advanced NSCLC in
over 25 countries, including Japan and the USA, gefitinib has demonstrated
significant clinical benefit in a disease area with limited treatment options.
& 2004 Elsevier Ltd. All rights reserved.Introduction
Lung cancer is a significant public health problem.
It is one of the most common forms of cancer—1.2
million new cases of lung cancer were diagnosed
worldwide in 2000—followed by breast cancer
(1.05 million new cases) and colorectal cancer
(945,000 new cases).1 The disease is a leading
cause of cancer death in both men and womenElsevier Ltd. All rights reserv
2-601-261; fax: +49-4102-
line.de (M. Reck).
straZeneca, Bristol-Myers
re Fabre.
for AstraZeneca and Lilly,
l-Myers Squibb and Pierreworldwide, accounting for an estimated 1.1 million
deaths in 2000,1 and approximately 80% of all lung
cancer cases are non-small-cell lung cancer
(NSCLC).
Symptoms of NSCLC
Evaluation of the signs and symptoms of lung
cancer can provide important information regard-
ing a patient’s disease stage and prognosis. In
general, lung cancer patients initially present with
a wide variety of symptoms, often related to the
respiratory tract, such as cough, dyspnea, chest
pain, hemoptysis, and hoarseness.2 More general
symptoms include fever, bone pain, weakness,
weight loss, anorexia, neuropathic pain, headache,
confusion, and ataxia.ed.
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large airways can produce local symptoms, includ-
ing cough, localized wheezing, hemoptysis, or
dyspnea.3 Locally advanced tumors will usually
generate systemic symptoms, such as fatigue,
weight loss, and fever. Individual symptoms may
provide more specific information; for example,
hoarseness can result from mediastinal invasion of
the recurrent laryngeal nerve. Distant metastatic
disease may also cause symptoms that aid evalua-
tion and prognosis. Metastases from lung cancer
have been found in every organ; however, the four
most common sites of metastases are the adrenal
glands, liver, central nervous system, and bone.
Disease-related symptoms cause a great deal of
distress to the patient and, together with the
general psychologic and social impact of cancer,
can seriously compromise overall quality of life
(QoL). It is increasingly recognized that improve-
ment in symptoms and QoL are important endpoints
in the evaluation of new anticancer treatments.Treatment options for advanced NSCLC
Surgery is the treatment of choice for early stage (I
and II) NSCLC, while a multidisciplinary approach,
combining surgery, chemotherapy, and radiother-
apy, offers the best chance of a cure for locally
advanced disease (IIIa and IIIb). Approximately half
of all patients with early stage or locally advanced
NSCLC are treated non-surgically, either because
they are unable to tolerate surgical resection, or
because their tumor is considered to be unresect-
able (stage III disease). Platinum-based chemother-
apy combinations are well-established first-line
treatments for patients with advanced NSCLC
(stage IV disease); however, chemotherapy is
associated with significant toxicity and limited
efficacy. A high proportion of patients relapse and
only docetaxel is the only chemotherapy agent
currently approved for second-line therapy.4,5
Despite improvements in the treatment of NSCLC,
approximate 5-year survival rates are: 65% (stage I
disease); 40% (stage II disease); 15% (stage III
disease); 5% (stage IV disease).6 The 1-year survival
rate for patients with advanced recurrent NSCLC is
also poor: for those patients receiving best suppor-
tive care after at least one chemotherapy regimen,
1-year survival is 16%7 and a retrospective analysis
of patients receiving third- and fourth-line che-
motherapy reported 5.5% 1-year survival.8 There is
an urgent need for more effective and less toxic
treatments for patients with advanced NSCLC.Novel biologic agents are currently being inves-
tigated for the treatment of NSCLC. These ration-
ally designed therapeutics offer hope that better-
tolerated treatment options, which provide clinical
benefit, may be found. The current status of
development of a selection of these new therapeu-
tic agents is summarized in Table 1.9–36 The
epidermal growth factor receptor (EGFR) is an
important therapeutic target. This cell membrane
receptor has intrinsic tyrosine kinase (TK) activity
and exists as a monomer that dimerizes following
ligand binding. Dimerization activates the intrinsic
TK domain, resulting in tyrosine autophosphoryla-
tion and the initiation of numerous downstream
signaling pathways.37–40
The EGFR mediates cell signaling associated with
tumor development, such as increased cell prolif-
eration and decreased apoptosis.37–40 Furthermore,
expression or high expression of the EGFR is seen in
a wide variety of human tumors, including most
NSCLCs.41–44 The EGFR has therefore been impli-
cated in the pathogenesis of several human tumors
and forms a key target for novel anticancer
therapies. A number of promising agents have been
designed to antagonize EGFR function,45 such as
monoclonal antibodies (cetuximab [Erbitux]) and
small-molecule EGFR-TK inhibitors (EGFR-TKIs) (ge-
fitinib [‘Iressa’] and erlotinib [Tarceva]). Current
clinical investigations of gefitinib encompass a
variety of human malignancies such as head and
neck, breast, and colorectal cancer.46 However,
gefitinib is furthest advanced in clinical develop-
ment for the treatment of NSCLC: to date,
approximately 150,000 patients have received
gefitinib worldwide and it is the first EGFR-TKI to
have been licensed. The indication in Japan is for
inoperable or recurrent disease. In the USA and
Australia, gefitinib monotherapy has recently been
approved for the treatment of locally advanced or
metastatic NSCLC after the failure of both plati-
num-based and docetaxel chemotherapies.Gefitinib
Gefitinib is an orally active EGFR-TKI that blocks
signal transduction pathways implicated in the
proliferation and survival of cancer cells, and other
host-dependent processes promoting cancer cell
growth.38 Gefitinib has an intracellular mechanism
of action. It competes with ATP for binding to the
EGFR, thus directly inhibiting EGFR autophosphor-
ylation. In vitro studies have demonstrated that
gefitinib reduces cell proliferation, increases apop-
tosis, and inhibits angiogenesis.47,48 In preclinical
studies, gefitinib demonstrated tumor growth in-
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Table 1 Examples of novel biologic agents in clinical development for the treatment of NSCLC.
Drug Mechanism of action Current status of development in
NSCLC
References
Gefitinib (‘Iressa’) EGFR-TKI Approved in over 25 countries (see
text for indications)
Fukuoka et al.9, Kris et al.10
Erlotinib (Tarceva, OSI-774) EGFR-TKI Phase III as single agent and in
combination with standard
chemotherapy
Herbst et al.11, Gatzemeier et
al.12, Shepherd et al.13
Cetuximab (Erbitux, IMC-C225) Anti-EGFR monoclonal antibody Phase III in combination with
standard chemotherapy
Data not yet available
Phase I/II in combination with
standard chemotherapy
Kelly et al.14, Kim et al.15, Robert
et al.16, Rosell et al.17
Bevacizumab (Avastin, rhuMab-
VEGF)
Humanized anti-VEGF monoclonal
antibody
Phase I/II as single agent and in
combination with erlotinib
Langmuir et al.18, Novotny et al.19,
Sandler et al.20
Lonafarnib (Sarasar, SCH 66336) Farnesyl-transferase inhibitor Phase III in combination with
taxanes
Data not yet available
Phase I/II as single agent and in
combination with standard
chemotherapy
Adjei et al.21, Hurwitz et al.22,
Khuri et al.23, Kim et al.24, Lipton
et al.27, Pierson et al.26, Sprague
et al.28, Zaknoen et al.25
Bexarotene (Targretin, LGD1069) Binds nuclear hormone receptors
and directly mediates gene
expression
Phase III in combination with
standard chemotherapy
Data not yet available
Phase I/II as single agent and in
combination with standard
chemotherapy
Jacobs et al.29, Khuri et al.30, Rizvi
et al.31, Yocum et al.32
ISIS 3521 (Affinitac, LY-900003) Protein kinase Ca antisense Phase III in combination with
standard chemotherapy
Lynch et al.33
Phase I/II in combination with
standard chemotherapy
Moore et al.34, Ritchs et al.35 Yuen
et al.36
Oblimersen (Genasense, G-3139) Bcl-2 antisense Phase III in combination with
docetaxel
Data not yet available
EGFR, epidermal growth factor receptor; EGFR-TKI, EGFR tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.
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Figure 1 Functional Assessment of Cancer Therapy-Lung
(FACT-L), showing the Trial Outcome Index (TOI) and the
Lung Cancer Subscale (LCS) items.
Gefitinib: a new therapy for advanced NSCLC 301hibition in a wide range of tumor cell lines and
human tumor xenograft models, including lung,
breast, colon, and prostate cancers.47,49–52 These
results supported the clinical development of
gefitinib as an anticancer agent.
Four large, multicenter, Phase I trials investi-
gated the dose escalation of gefitinib up to
1000mg/day in 254 patients with a range of solid
malignancies.53–56 Encouraging antitumor activity
was observed, particularly in NSCLC: 10 out of 100
patients with NSCLC experienced a partial response
across a range of doses. These trials demonstrated
the acceptable tolerability profile and ease of
administration of gefitinib. Adverse events were
mostly mild (grade 1/2); the most common were
rash/acne and diarrhea. Dose-limiting toxicity was
observed at 700–1000mg/day, while responses
occurred from 150–700mg/day. These data sup-
ported the selection of 250 and 500mg/day doses
for Phase II trials of gefitinib.
Two large, randomized, double-blind, Phase II
studies continued the investigation of gefitinib
monotherapy for the treatment of NSCLC. The
‘Iressa’ Dose Evaluation in Advanced Lung cancer
(IDEAL) 1 and 2 trials each recruited approximately
200 patients with locally advanced or metastatic
NSCLC and compared gefitinib doses of 250 and
500mg/day.9,10 In IDEAL 1, patients had received
one or two prior chemotherapy regimens, while
patients enrolled in IDEAL 2 had received at least
two previous chemotherapy regimens and were
required to be symptomatic for NSCLC at baseline.
Although this was not a requirement for IDEAL 1,
64% and 69% of patients in the 250 and 500mg/day
groups were symptomatic for NSCLC at trial entry.
In both trials, key endpoints included objective
response rate, symptom relief, QoL, safety profile,
and survival.
Symptom improvement in Phase II trials
Gefitinib demonstrated significant improvement in
disease-related symptoms in both IDEAL 1 and 2, as
assessed by the Lung Cancer Subscale (LCS) of the
Functional Assessment of Cancer Therapy–Lung
(FACT-L)57,58 (Fig. 1 and Table 2). The LCS and
FACT-L have been independently validated and
shown to provide clinically meaningful information
about symptoms commonly experienced by lung
cancer patients and their QoL.57,58
A total of 356 patients in IDEAL 1 and 2 were
evaluable for symptom improvement, with median
baseline LCS scores of 16–18. Symptom improve-
ment was demonstrated in 40% and 43% of evalu-
able patients at 250mg/day, and 37% and 35% of
patients at 500mg/day, in IDEAL 1 and 2, respec-
tively.9 At both dose levels, symptom improvementwas rapid, with a median time to improvement of
8–10 days in both trials.59 Furthermore, LCS
responses were durable, with median durations of
symptom improvement of 5.1 months (IDEAL 1) and
5.4 months (IDEAL 2) observed in the 500mg/day
dose group (not yet reached at data cut-off for the
250mg/day group in both trials).
Analysis of improvements in individual LCS items
showed that high proportions of patients reported
improvements in pulmonary symptoms (IDEAL 2
data shown in Fig. 2; similar results were seen in
IDEAL 1). The LCS items of difficulty breathing and
shortness of breath showed the greatest improve-
ment in IDEAL 2: these items were both improved in
89% of patients with LCS improvement at 250mg/
day. Comparison of individual LCS item scores at
baseline with on-study best scores showed marked
increases in the proportion of patients reporting
individual items as asymptomatic, together with
fewer items reported as very symptomatic (eg.
IDEAL 2 data shown in Fig. 3).
The LCS data showed a positive correlation with
objective tumor response. The majority of patients
with a partial/complete response (69% in IDEAL 1
and 100% in IDEAL 2 at 250mg/day) or with stable
disease (70% in IDEAL 1 and 81% in IDEAL 2 at
250mg/day) experienced clinically significant im-
provement in disease-related symptoms, whereas
for patients with progressive disease, the symptom-
improvement rate was relatively low (12% in both
IDEAL 1 and 2 at 250mg/day). Furthermore,
patients with symptom improvement had longer
overall and progression-free survival: for example,
in IDEAL 2 at 250mg/day, median overall survival in
patients with symptom improvement was 13.6
months compared with 3.7 months in patients
who did not experience symptom improvement.
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Table 2 Assessment of disease-related symptoms and QoL.
Disease-related symptoms QoL
Method of assessment LCS, a subscale of the validated
QoL instrument, the FACT-L
questionnaire57
FACT-L questionnaire, validated
with respect to its psychometric
properties and sensitivity to
clinical changes57
The 7 LCS items:
(1) Shortness of breath
(2) Cough
(3) Tightness in chest
(4) Difficulty breathing
(5) Loss of appetite
(6) Weight loss
(7) Lack of clear thinking
TOI measures the more physical
aspects of FACT-L shown to be
sensitive to chemotherapy
TOI covers:
(1) Symptoms (LCS)
(2) Physical wellbeing
(3) Functional wellbeing
Frequency of assessment
Patients completed a weekly
diary card, rating each item on a
scale of 0–4
FACT-L was completed at
baseline, and on day 28 of each
treatment period (before clinical
assessment and before patients
were informed of their disease
status)
Maximum (best; asymptomatic)
score attainable
LCS: 28 TOI: 84
FACT-L: 136
Prospectively defined clinically
meaningful improvement
X2-point improvement for X4
weeks, with no worsening at any
interim timepoints58
X6-point improvement for X4
weeks
FACT-L, Functional Assessment of Cancer Therapy-Lung; LCS, Lung Cancer Subscale; QoL, quality of life; TOI, Trial Outcome
Index.
Figure 2 Specific symptom improvement in all patients with Lung Cancer Subscale improvement (IDEAL 2, 250mg/day).
M. Reck, U. Gatzemeier302These results provide further evidence of the
clinical relevance of symptom improvement as a
trial endpoint, in addition to the clear benefit
experienced by the patient.QoL in Phase II trials
The complete FACT-L questionnaire evaluated QoL
and its subset, the Trial Outcome Index (TOI),
assessed the more physical aspects of FACT-L57,58
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Table 3 QoL improvement rates (250mg/day).
IDEAL 1 (n ¼ 67) IDEAL 2 (n ¼ 102)
Response (%) TOI FACT-L TOI FACT-L
Improved 20.9 23.9 33.3 34.3
No change 26.9 14.9 14.7 12.7
Worsened 9.0 19.4 5.9 6.9
Othera 43.3 41.8 46.1 46.1
aPatients to whom a response could not be assigned, e.g. due to missing data. FACT-L, Functional Assessment of Cancer
Therapy-Lung; IDEAL, ‘Iressa’ Dose Evaluation in Advanced Lung cancer; QoL, quality of life; TOI, Trial Outcome Index.
Figure 3 Comparison of individual Lung Cancer Subscale item scores at baseline and on-study best score (IDEAL 2,
250mg/day).
Gefitinib: a new therapy for advanced NSCLC 303(Fig. 1 and Table 2). In both IDEAL 1 and 2, patients
had compromised QoL at trial entry. Compared with
maximum (asymptomatic) scores of 84 for the TOI
and 136 for FACT-L, the median baseline scores
were 53 and 49 (TOI) and 85 and 86 (FACT-L) in
IDEAL 1 and 2, respectively.
Gefitinib treatment resulted in QoL FACT-L
improvement in 24% and 34% of patients at
250mg/day (IDEAL 1 and 2, respectively)
(Table 3). As observed with the LCS symptom
data, improvements in QoL were associated
with tumor response: 54% and 92% of patients with
an objective response in IDEAL 1 and 2, respec-
tively, showed improvement in overall FACT-L
scores.
Objective tumor response in Phase II trials
Gefitinib treatment resulted in clinically mean-
ingful antitumor activity in both trials, assessedusing the Southwest Oncology Group-modified
International Union Against Cancer/World Health
Organization criteria. Objective response rates
were 18% and 19% in IDEAL 1, and 12% and 9% in
IDEAL 2 at 250 and 500mg/day, respectively. In
addition to the patients who experienced objective
tumor responses, approximately 30% of patients in
both trials achieved stable disease, resulting in
disease control rates of 54% and 51% in IDEAL 1, and
42% and 36% in IDEAL 2 at 250 and 500mg/day,
respectively. Median overall survival times in the
250 and 500mg/day groups were 7.6 and 7.9
months (IDEAL 1), and 6.5 and 5.9 months (IDEAL
2), respectively. The estimated 1-year survival
rates were 35% and 29% (IDEAL 1) and 29% and
24% (IDEAL 2) for the 250 and 500mg/day dose
groups, respectively. These results demonstrated
no difference in efficacy between the two doses of
gefitinib.
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Gefitinib was generally well tolerated in both IDEAL
1 and 2. The most common adverse events were
mild: National Cancer Institute Common Toxicity
Criteria (version 2.0) grade 1/2 gastrointestinal and
skin-related adverse events. Fewer patients had
grade 3/4 adverse events with 250mg/day than
with 500mg/day (8.7% versus 30.2% in IDEAL 1 and
6.9% versus 17.5% in IDEAL 2, respectively). Over-
all, the 250mg/day dose was better tolerated than
500mg/day and this, combined with similar results
for efficacy endpoints with the two doses, makes
250mg/day the recommended dose for patients
with NSCLC who have previously received che-
motherapy. This dissociation of dose–response and
dose–toxicity relationships was forecast for biologic
agents such as gefitinib.60 Direct targeting of
malignant cells was expected to reduce toxicity
at clinically effective doses. In this model, assess-
ment of the maximum tolerated dose is not an
appropriate endpoint and concepts such as the
optimal biologic dose are more meaningful. This
alternative outcome aims to elucidate the dose
that provides maximum efficacy while maintaining
a favorable tolerability profile. Evidence from the
IDEAL trials suggests that gefitinib conforms to this
model and that 250mg/day is the optimal biologic
dose of gefitinib in NSCLC.Phase III trails
Two large, randomized, double-blind, placebo-
controlled, Phase III trials, each of approximately
1000 previously untreated patients with NSCLC,
investigated gefitinib in combination with gemcita-
bine/cisplatin (the ‘Iressa’ NSCLC Trial Assessing
Combination Treatment [INTACT] 1), or carbopla-
tin/paclitaxel (INTACT 2).61,62 Despite showing no
additional benefit in efficacy, there was no worsen-
ing of chemotherapy-associated toxicities, thus
confirming the favorable tolerability of gefitinib in
the placebo-controlled setting. The most common
adverse events were gastrointestinal, skin relatedTable 4 Incidence of pulmonary adverse events in INTAC
Gefitinib
500mg/day
(n ¼ 700)
Dyspnea, n (%) 181 (25.9)
Cough, n (%) 146 (20.9)
Pneumonia, n (%) 43 (6.1)
ILD event, n (%) 8 (1.1)
INTACT, ‘Iressa’ NSCLC Trial Assessing Combination Treatment; IL(both as expected from previous studies of gefiti-
nib), and hematologic (as expected from the
toxicity profiles of gemcitabine/cisplatin and pa-
clitaxel/carboplatin). The frequency of adverse
events was similar across all treatment arms,
except for diarrhea, rash, and acne, which showed
a gefitinib dose–response relationship. The inci-
dence of pulmonary adverse events, including
interstitial lung disease (ILD)-type events, was
generally similar in treatment arms in INTACT 1
and 2 (Table 4).
It is unclear why the combination of gefitinib
with standard doublet chemotherapy failed to show
survival benefits in the first-line setting. Possible
explanations include a pharmacodynamic antagon-
ism between the drugs, or that treatment with
chemotherapy sensitizes tumors to EGFR-targeted
therapy, so that gefitinib is more effective in
pretreated patients. These results reinforce the
need for better understanding of the activity of
gefitinib in a wider range of tumor types, treatment
strategies, and patient subgroups. Erlotinib, an-
other EGFR-TKI, has also been investigated in
combination with standard chemotherapy in pa-
tients with metastatic NSCLC in the first-line
setting in two Phase III trials. As with gefitinib,
overall survival (the primary endpoint) was not
improved.Compassionate-use program
More than 44,000 patients worldwide have received
gefitinib as part of a compassionate-use program.
These patients have advanced (inoperable stage III
or IV) NSCLC, do not qualify for clinical trials, and
have exhausted other treatment options. As well as
providing patients with earlier access to this novel
therapy for NSCLC, this program has imparted a
considerable amount of valuable clinical informa-
tion on the use of gefitinib. Gefitinib has demon-
strated clinical activity in terms of objective tumor
response, disease control, and overall survival.63–66
In addition, tumor response has been related toT 1 and 2.
Gefitinib Placebo
250mg/day
(n ¼ 704) (n ¼ 696)
189 (26.8) 193 (27.7)
159 (22.6) 148 (21.3)
48 (6.8) 46 (6.6)
8 (1.1) 6 (0.9)
D, interstitial lung disease.
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21,000 patients who took part in this compassio-
nate-use program in the USA recently reported a 1-
year survival rate of 29.9%, which is consistent with
the IDEAL trial results.63 Tolerability data have
generally been consistent with previous studies,
with most adverse events observed being mild skin-
related or gastrointestinal disorders. In this wide
compassionate-use program, the incidence of ILD is
approximately 0.3%. In comparison, the incidence
of ILD in Japanese patients treated with gefitinib
has been reported as 1.7%.67 However, in approxi-
mately 140,000 patients worldwide treated with
gefitinib, the overall incidence of ILD is less than
1%. It is difficult to determine the exact cause for
this condition in these patients, as these events
may have been due to progression of the lung
cancer, prior therapy, or gefitinib treatment.
Hence, a direct relationship between gefitinib and
ILD is unclear in many cases.Potential prognostic factors
For a variety of NSCLC treatment strategies, many
research efforts have focused on investigating
clinical and biologic factors that may predict which
patients will benefit from treatment. Emerging
data have identified specific somatic EGFR muta-
tions in patients with dramatic responses to
gefitinib.68,69 This provides an exciting insight into
why some patients experience such dramatic
responses to gefitinib and also confirms that this
is a targeted therapy. However, the role of these
mutations in other clinical benefits seen with
gefitinib such as disease stabilization and/or
symptom improvement is not yet known and further
molecular studies are ongoing to explain the
mechanisms responsible for these benefits.Conclusions
Patients with NSCLC often present with pulmonary
symptoms; therefore, treatment strategies should
aim to provide disease-related symptom relief and
improved QoL. These are important endpoints in
the clinical evaluation of novel therapies for
cancer, and this is further supported by their
observed correlation with objective tumor re-
sponse and survival. In recent trials, the oral
EGFR-TKI gefitinib has demonstrated improvement
in pulmonary symptoms and QoL in pretreated
patients with advanced NSCLC. In addition, gefiti-
nib monotherapy resulted in clinically significant
antitumor activity and displayed a favorable toler-
ability profile. The combination of gefitinib withplatinum-based chemotherapy doublets in the first-
line setting for NSCLC produced no additional
survival benefit. A large-scale compassionate-use
program has provided extensive clinical experience
with gefitinib therapy. Gefitinib has demonstrated
antitumor activity and good tolerability in these
patients and further results from this program are
awaited with interest. To conclude, treatment with
gefitinib has demonstrated significant clinical ben-
efit for patients with advanced NSCLC and, in
particular, provides rapid relief from the pulmonary
symptoms that are commonly associated with this
disease.
‘Iressa’ is a trademark of the AstraZeneca group
of companies.References
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